Download PDF
Drug Res (Stuttg) 2018; 68(01): 33-37
DOI: 10.1055/s-0043-116948
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Attenuation of Morphine-Induced Tolerance and Dependence by Pretreatment with Cerebrolysin in Male rats

Hamed Ghavimi
1   Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zanjan University of Medical Science, Zanjan, Iran
,
Sara Darvishi
2   Student Research Committee, Zanjan University of Medical Science, Zanjan, Iran
,
Saeed Ghanbarzadeh
3   Zanjan Pharmaceutical Nanotechnology Research Center, and Department of Pharmaceutics, Faculty of Pharmacy, Zanjan University of Medical Science, Zanjan, Iran
› Author Affiliations
Further Information

Publication History

received 12 January 2017

accepted 18 July 2017

Publication Date:
28 August 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background Dependence and tolerance to morphine are major problems which limit its chronic clinical application.

Purpose This study was aimed to investigate the attenuation effect of Cerebrolysin, a mixture of potent growth factors (BDNF, GDNF, NGF, CNTF etc,), on the development of Morphine-induced dependence and tolerance.

Methods Male Wistar rats were selected randomly and divided into different groups (n=8) including: a control group, groups received additive doses of morphine (5–25 mg/kg, ip, at an interval of 12 h until tolerance completion), and groups pretreated with Cerebrolysin (40, 80 and 160 mg/kg, ip, before morphine administration). Development of tolerance was assessed by tail-flick test and the attenuation effect of Cerebrolysin on morphine-induced dependence was evaluated after injection of naloxone (4 mg/kg, ip, 12 h after the morning dose of morphine). Seven distinct withdrawal signs including: jumping, rearing, genital grooming, abdominal writhing, wet dog shake and teeth grinding were recorded for 45 min and total withdrawal score (TWS) was calculated.

Results Results showed that administration of Cerebrolysin could prolonged development (10 and 14 days in administration of 80 mg/kg and 160 mg/kg Cerebrolysin) and completion (4, 10 and 14 days in administration of 40, 80 and 160 mg/kg Cerebrolysin, respectively) of tolerance. Results also indicated that administration of Cerebrolysin (40, 80 and 160 mg/kg) could significantly decreased the TWS value (62±2, 77±4 and 85±6%, respectively).

Conclusion In conclusion, it was found that pretreatment with Cerebrolysin could attenuated morphine-induced tolerance and dependence.

Key words

morphine - tolerance - dependence - cerebrolysin
 

  • References

  • 1 Hutchinson MR, Coats BD, Lewis SS. et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun. 2008; 22: 1178-1189
    CrossrefPubMedGoogle Scholar
  • 2 Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251: 85-87
    CrossrefPubMedGoogle Scholar
  • 3 Pajohanfar NS, Mohebbi E, Rad A. et al. Protective effects of atorvastatin against morphine-induced tolerance and dependence in mice. Brain Research. 2017; 1657: 333-339
    CrossrefPubMedGoogle Scholar
  • 4 Rahmati B, Beik A. Prevention of morphine dependence and tolerance by Nepeta menthoides was accompanied by attenuation of Nitric oxide overproduction in male mice. Journal of Ethnopharmacology 2017; 199: 39-51
    CrossrefPubMedGoogle Scholar
  • 5 Salmanzadeh H, Azizi H, Semnanian S. Adolescent chronic escalating morphine administration induces long lasting changes in tolerance and dependence to morphine in rats. Physiology & Behavior 2017; 174: 191-196
    CrossrefPubMedGoogle Scholar
  • 6 Guekht AB, Moessler H, Novak PH. et al. Cerebrolysin in vascular dementia: Improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases 2011; 20: 310-318
    CrossrefPubMedGoogle Scholar
  • 7 Khalili H, Niakan A, Ghaffarpasand F. Effects of cerebrolysin on functional recovery in patients with severe disability after traumatic brain injury: A historical cohort study. Clinical Neurology and Neurosurgery 2017; 152: 34-38
    CrossrefPubMedGoogle Scholar
  • 8 Liu Z, Hu M, Lu P. et al. Cerebrolysin alleviates cognitive deficits induced by chronic cerebral hypoperfusion by increasing the levels of plasticity-related proteins and decreasing the levels of apoptosis-related proteins in the rat hippocampus. Neuroscience Letters. 2017; 651: 72-78
    CrossrefPubMedGoogle Scholar
  • 9 Morales-Medina JC, Griffiths NH, Flores G. et al. Cerebrolysin reduces mechanical allodynia in a rodent model of peripheral inflammation. Neuroscience Letters. 2017; 642: 27-30
    CrossrefPubMedGoogle Scholar
  • 10 Noor NA, Mohammed HS, Mourad IM. et al. A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease. Life Sciences. 2016; 155: 174-179
    CrossrefPubMedGoogle Scholar
  • 11 Pourmemar E, Majdi A, Haramshahi M. et al. Intranasal cerebrolysin attenuates learning and memory impairments in d-galactose-induced senescence in mice. Experimental Gerontology. 2017; 87 Part A 16-22
    CrossrefPubMedGoogle Scholar
  • 12 Baran H, Kepplinger B. Cerebrolysin lowers kynurenic acid formation — An in vitro study. European Neuropsychopharmacology. 2009; 19: 161-168
    CrossrefPubMedGoogle Scholar
  • 13 Huang T-L, Huang S-P, Chang C-H. et al. Protective effects of cerebrolysin in a rat model of optic nerve crush. The Kaohsiung Journal of Medical Sciences 2014; 30: 331-336
    CrossrefPubMedGoogle Scholar
  • 14 Kulikov A, Abdrashitova G. PRM129 - Cost-Effectiveness analysis of cerebrolysin in the treatment of patients with acute ischemic stroke moderate and severe degrees of severity in the russian federation. Value in Health. 2015; 18: A705
    PubMedGoogle Scholar
  • 15 Lucas B, Pinkernelle J, Fansa H. et al. Effects of cerebrolysin on rat Schwann cells in vitro. Acta Histochemica. 2014; 116: 820-830
    CrossrefPubMedGoogle Scholar
  • 16 Gorbachevskaya N, Bashina V, Gratchev V. et al. Cerebrolysin therapy in Rett syndrome: Clinical and EEG mapping study. Brain and Development 2001; 23 (Suppl. 01) S90-S93
    CrossrefPubMedGoogle Scholar
  • 17 Masliah E, Armasolo F, Veinbergs I. et al. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein e-deficient mice. Pharmacology Biochemistry and Behavior. 1999; 62: 239-245
    CrossrefPubMedGoogle Scholar
  • 18 Schwab M, Schaller R, Bauer R. et al. Morphofunctional effects of moderate forebrain ischemia combined with short-term hypoxia in rats — protective effects of Cerebrolysin. Experimental and Toxicologic Pathology. 1997; 49: 29-37
    CrossrefPubMedGoogle Scholar
  • 19 Charkhpour M, Jafari RM, Ghavimi H. et al. Duloxetine Attenuated Morphine Withdrawal Syndrome in the Rat. Drug Res 2013; 21: 21
    PubMedGoogle Scholar
  • 20 Moradi S, Charkhpour M, Ghavimi H. et al. Gap junction blockers: A potential approach to attenuate morphine withdrawal symptoms. J Biomed Sci. 2013; 20: 77
    CrossrefPubMedGoogle Scholar
  • 21 Riahi E, Mirzaii-Dizgah I, Karimian SM. et al. Attenuation of morphine withdrawal signs by a GABAB receptor agonist in the locus coeruleus of rats. Behav Brain Res. 2009; 196: 11-4
    CrossrefPubMedGoogle Scholar
  • 22 Abdel-Zaher AO, Mostafa MG, Farghaly HSM. et al. Role of oxidative stress and inducible nitric oxide synthase in morphine-induced tolerance and dependence in mice. Effect of alpha-lipoic acid. Behavioural Brain Research. 2013; 247: 17-26
    CrossrefPubMedGoogle Scholar
  • 23 Abdel-Zaher AO, Mostafa MG, Farghly HM. et al. Inhibition of brain oxidative stress and inducible nitric oxide synthase expression by thymoquinone attenuates the development of morphine tolerance and dependence in mice. European Journal of Pharmacology 2013; 702: 62-70
    CrossrefPubMedGoogle Scholar
  • 24 Sharma HS, Sharma A, Mössler H. et al. Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermia-induced neurotoxicity: Modulatory roles of co-morbidity factors and nanoparticle intoxication academic press. International review of neurobiology 2012; 102: 249-276
    PubMedGoogle Scholar
  • 25 Sharma HS, Castellani RJ, Muresanu DF. et al. Diabetes exacerbates Alzheimer's disease induced brain pathology. Possible neuroprotective effects of Cerebrolysin. Journal of the Neurological Sciences 2013; 333 (Suppl. 01) e301
    PubMedGoogle Scholar
  • 26 García EH, Guzmán DC, Olguín HJ. et al. Effect of cerebrolysin on the levels of glutathione and 5-HT in different regions of rat brain in presence of dantrolene. Biomedicine & Aging Pathology 2011; 1: 169-174
    CrossrefPubMedGoogle Scholar
  • 27 Rockenstein E, Desplats P, Ubhi K. et al. Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease. Stem Cell Research 2015; 15: 54-67
    CrossrefPubMedGoogle Scholar
  • 28 Sharma HS, Ali SF, Patnaik R. et al. Cerebrolysin attenuates heat shock protein (hsp 72 kd) expression in the rat spinal cord following morphine dependence and withdrawal: Possible new therapy for pain management. Curr. Neuropharmacol. 2011; 9: 223-235
    CrossrefPubMedGoogle Scholar